Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

MedImmune Appoints Development Leadership Team

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Former Cambridge Antibody Technology exec to oversee product development.

You may also be interested in...



AstraZeneca Concentrates Biologics At MedImmune, Ups R&D

MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.

AstraZeneca Hears CAT’s Meow With Biotech Acquisition

Deal for Cambridge Antibody Technology, valued at $1.07 bil., will shift focus of AstraZeneca’s pipeline.

Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD

Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Accelerated Approval: Potential Sources Of Confirmatory Evidence Weighed At Tofersen Review

PBM Transparency Act Advances In Senate And It’s A Far Cry From The Rebate Rule

Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl

EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’

See All
UsernamePublicRestriction

Register

PS067855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By